The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

UCB Biopharma SRL
Principal Investigator(s)
Dr. Yamane Makke
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.